DHIREN PATEL: Open Payments
NPI 1528078466 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,958 in 167 payments from 22 companies in 2025. Trend: 2023 $3,143 · 2024 $4,132 · 2025 $2,958
Food & beverage: $2,958
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $449 |
| Otsuka America Pharmaceutical, Inc. | 18 | $370 |
| Corium, LLC | 20 | $324 |
| Janssen Pharmaceuticals, Inc | 14 | $279 |
| Axsome Therapeutics, Inc. | 12 | $209 |
| Lundbeck LLC | 9 | $198 |
| Tris Pharma Inc | 16 | $174 |
| Supernus Pharmaceuticals, Inc. | 16 | $172 |
| Almatica Pharma LLC | 9 | $151 |
| Collegium Pharmaceutical, Inc. | 6 | $93 |
Products named: REXULTI, CAPLYTA, Azstarys, SPRAVATO, Auvelity, Dyanavel XR, Qelbree, LOREEV XR.
Industry payments across TX — which companies pay providers there.
